Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Inclusion Criteria: 1. Adult male and female patients ≥ 18 to ≤ 75 years of age upon study consent; 2. BMI \> 18.5 kg/m² 3. Symptomatic pulmonary hypertension WHO class II and III; 4. WHO Group I, III, or V PH according to the following criteria: 1. If diagnosed with WHO Group I PAH, then on of the following subtypes: * Idiopathic or heritable PAH; * PAH associated with connective tissue disease; * PAH associated with simple, congenital systemic-to-pulmonary shunts at least 1 year following shunt repair; * PAH associated with anorexigen or drug-induced toxicity; * PAH associated with human immunodeficiency virus (HIV); or 2. If WHO Group III PH then primary diagnosis must be one of the following subtypes: * Connective tissue disease associated ILD (CTD-ILD); * Idiopathic pulmonary fibrosis (IPF); * Nonspecific interstitial pneumonia (NSIP); or 3. If WHO Group V PH then patient must be diagnosed with sarcoidosis; 5. Had a diagnostic right heart catheterization performed and documented within 36 months prior to Day 1 that confirmed a diagnosis of PH 6. If WHO Group I, has been receiving no more than three (3) FDA-approved disease-specific PAH therapies except for intravenous (iv) prostacyclin/prostacyclin analogues. PAH therapy must be at a stable dose for at least 90 days prior to Day 1; 7. Has adequate kidney function defined as an estimated glomerular filtration rate (eGFR) ≥ 45 mL/min/1.73 m2 using the Modification of Diet in Renal Disease (MDRD) 4-variable formula; Exclusion Criteria: 1. Participation in other interventional clinical studies involving pharmaceutical products being tested or used in a way different from the approved form or when used for an unapproved indication within 30 days prior to Day 1; 2. Initiation of an exercise program for cardio-pulmonary rehabilitation within 3 months (90 days) prior to Day 1 or planned initiation during Part 1 of the study; 3. Stopped receiving any PH chronic therapy within 60 days prior to Day 1; 4. Requirement for receipt of intravenous inotropes within 30 days prior to Day 1; 5. Has uncontrolled systemic hypertension as evidenced by sitting systolic blood pressure (BP) \> 160 mm Hg or sitting diastolic blood pressure \> 100 mm Hg during Screening after a period of rest; 6. Has systolic BP \< 90 mm Hg during Screening after a period of rest; 7. WHO Group III or V patients who at rest require supplemental oxygen at a rate of \>4 L/min and have peripheral capillary oxygen saturation levels \<92%; 8. Has a history of clinically significant left-sided heart disease and/or clinically significant cardiac disease,including but not limited to any of the following: 1. Congenital or acquired valvular disease if clinically significant apart from tricuspid valvular insufficiency due to pulmonary hypertension; 2. Pericardial constriction; 3. Restrictive or congestive cardiomyopathy; 4. Left ventricular ejection fraction \< 40% per echocardiogram (ECHO) within 60 days of Day 1; 5. Any current or prior history of symptomatic coronary disease (prior myocardial infarction, percutaneous coronary intervention, coronary artery bypass graft surgery, or anginal chest pain); 9. Acutely decompensated heart failure within 30 days prior to Day 1, as per Investigator assessment; 10. History of atrial septostomy within 180 days prior to Day 1; 11. History of obstructive sleep apnea that is untreated; 12. Has a history of portal hypertension or chronic liver disease, including hepatitis B and/or hepatitis C (with evidence of recent infection and/or active virus replication) defined as mild to severe hepatic impairment (Child-Pugh Class A-C); 13. Serum aminotransferase (ALT or AST) levels \> the upper limit of normal (ULN) at Screening; 14. For patients with HIV-associated PAH, any of the following: 1. Concomitant active opportunistic infections within 180 days prior to Screening; 2. Detectable viral load within 90 days prior to Screening; 3. Cluster designation (CD+) T-cell count \< 200 mm3 within 90 days prior to Screening; 4. Changes in antiretroviral regimen within 90 days prior to Screening; 5. Using inhaled pentamidine